Ruth L. Coleman

University of Oxford — United Kingdom

Medicine · Health Sciences

28h-index3.7kcitations131works9.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(47), Diabetes, Cardiovascular Risks, and Lipoproteins(28), Diabetes Management and Research(28), Cardiovascular Function and Risk Factors(23), Health Systems, Economic Evaluations, Quality of Life(14)

Publications128 total

Estimating the risk of cardiovascular outcomes and all‐cause mortality in individuals with type 2 diabetes: Validation of the <scp>UKPDS</scp> outcomes model using <scp>TECOS</scp> and <scp>EXSCEL</scp> data
Diabetes Obesity and Metabolism·2025Open Access
Author response for "Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS Outcomes Model using TECOS and EXSCEL data"
2025
Author response for "Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS Outcomes Model using TECOS and EXSCEL data"
2025
International Variations in Case Fatality Following Major Coronary or Cerebrovascular Events in People With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL
2025Open Access
International Variations in Case Fatality Following Major Coronary or Cerebrovascular Events in People With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL
2025Open Access
International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL
Diabetes Care·2025
Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis
Cardiovascular Diabetology·2025· 1 citedOpen Access
82P Comparative effectiveness of nab-paclitaxel and paclitaxel in patients with platinum-resistant ovarian cancer (COMPASS)
ESMO Open·2025Open Access
Glucocorticoid‐induced hyperglycaemia in hospitalised adults: A matched cohort study (2013–2023)
Diabetes Obesity and Metabolism·2025· 6 citedOpen Access
Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysis
Diabetes Research and Clinical Practice·2025· 8 citedOpen Access
Author response for "Glucocorticoid‐induced hyperglycaemia in hospitalised adults: A matched cohort study (2013–2023)"
2025
The legacy effect of hyperglycaemia in type 2 diabetes – Authors' reply
The Lancet·2025Open Access
Glucocorticoid treatment and new‐onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta‐analysis
Diabetic Medicine·2024· 2 citedOpen Access
Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92)
The Lancet Diabetes & Endocrinology·2024· 39 citedOpen Access
Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the <scp>EXSCEL</scp> trial
Diabetes Obesity and Metabolism·2024· 3 citedOpen Access
Author response for "Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the &lt;scp&gt;EXSCEL&lt;/scp&gt; trial"
2024
181-OR: Declining eGFR over Time Predicts the Risk of a Composite of Primary or Secondary Major Adverse Cardiovascular Events or Heart Failure Hospitalization, in People with Type 2 Diabetes—EXSCEL Post Hoc analysis
Diabetes·2024
1332-P: Young-Onset Type 2 Diabetes—UK Prospective Diabetes Trial (UKPDS) 30-Year Follow-up
Diabetes·2024
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)
The Lancet·2024· 117 citedOpen Access
Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial
Journal of Diabetes·2023· 3 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Rury R. Holman(42), Richard Stevens(9), Ewan R. Pearson(7), Amanda Adler(6), Kaixin Zhou(5), Olorunsola F. Agbaje(5), Charles A.B. Scott(5), Hertzel C. Gerstein(4), John J.V. McMurray(4), Joanne Milton(4), Sook Wah Yee(4), Joline W. J. Beulens(4), Michiaki Kubo(4), Leen M. ‘t Hart(4), Monique M. Hedderson(4), José C. Florez(4), M. Angelyn Bethel(4), Jaakko Tuomilehto(4), Zhihui Lang(3), Nienke van Leeuwen(3)